U.S. Emerging Pulmonary Drug Delivery Technologies Markets

Published by: Frost & Sullivan

Published: Jan. 16, 2003

Table of Contents

1 Executive Summary

A. Executive Summary

1 Executive Summary

2 Total Market

A. Overview

1 Introduction

2 Market Engineering Analysis

B. Forecasts and Trends

1 Phasing out of CFC MDIs

2 Demand Analysis

3 Patient Forecasts by Technology

4 Patient Forecasts by Application

5 Pricing Analysis

6 Revenue Forecasts

C. Challenges

1 Challenges Overview

2 Technological Inadequacies Threaten Survival

3 Past Experiences Tarnish Future Prospects and Limit Success

4 Unsure Product Approval Outcome Creates Ambiguity

5 Unproven Efficacy and Safety in Newer Applications Creates Uncertainty

6 Overzealous Technological Innovation Limits Success Odds

D. Market Engineering Awards

1 Marketing Strategy Leadership Award

2 Growth Strategy Market Engineering Award

3 Product Differentiation Innovation Award

4 Competitive Strategy Award

3 Non-CFC Metered Dose Inhalers Market

A. Overview

1 Introduction

2 Market Engineering Analysis

3 Market Drivers

4 Market Restraints

5 Competitive Structure

B. Forecast and Trends

1 Patient Forecasts

2 Pricing Analysis

3 Revenue Forecasts

C. Non-CFC Metered Dose Inhalers Technology

1 3M Drug Delivery Systems

2 Aeropharm Technologies Inc.

4 Dry Powder Inhalers Market

A. Overview

1 Introduction

2 Market Engineering Analysis

3 Market Drivers

4 Market Restraints

5 Competitive Structure

B. Forecast and Trends

1 Patient Forecasts

2 Pricing Analysis

3 Revenue Forecasts

4 Market Share Analysis

C. Dry Powder Inhalers by Application

1 Dry Powder Inhalers in Asthma/COPD

2 Dry Powder Inhalers in Cystic Fibrosis

3 Dry Powder Inhalers in Diabetes

4 Dry Powder Inhalers in Cancer

5 Dry Powder Inhalers in Migraine

D. Dry Powder Inhaler Technologies

1 Alkermes

2 Inhale Therapeutics

3 Microdose Technologies

4 Oriel Therapeutics

5 Respirics

6 Skye Pharma

5 Liquid-Based Inhalers Market

A. Overview

1 Introduction

2 Market Engineering Analysis

3 Market Drivers

4 Market Restraints

5 Competitive Structure

B. Forecast and Trends

1 Patient Forecasts

2 Pricing Analysis

3 Revenue Forecasts

C. Liquid-Based Inhalers by Application

1 Liquid-Based Inhalers in Asthma/COPD

2 Liquid-Based Inhalers in Cystic Fibrosis

3 Liquid-Based Inhalers in Diabetes

4 Liquid-Based Inhalers in Cancer

D. Liquid-Based Inhaler Technologies

1 Battelle Pharma

2 Aradigm Corporation

3 Aerogen

Abstract

The development of path breaking, non-invasive, pulmonary drug delivery technologies such as chlorofluorocarbons (CFC)-free metered dose inhalers (MDI), dry powder inhalers (DPI), and liquid-based inhalers (LBIs) invites many companies to enter the lucrative market, intensifying competition. The introduction of portable nebulizers will also offer revenue opportunities. Emergent pulmonary drug delivery technologies are competing to develop a simple and affordable device allowing for multiple dosage, consistent drug delivery, and high lung penetration. Design innovations have reduced the size of the device considerably, thereby increasing patient convenience.

This Frost & Sullivan research examines the U.S. Emerging Pulmonary Drug Delivery Technologies Markets. The report is segmented into Non-CFC MDI market, DPI market, and liquid-based inhalers market. The market has been sub-segmented by therapeutic area. Detailed patient and revenue forecasts have been provided for each product category and application.

Dubious FDA Stance Raises Product Approval Anxiety

"The growth in the number of patients, increasing cost of therapy, and expanding applications are the major factors that are expected to drive the growth," says the author of this research. However, the Food and Drug Administration's (FDA) rigorous product approval process poses a challenge to the market participants. Companies will find it difficult to crystallize introduction time lines unless there is a strong indication from the FDA. Also, as the phasing out of the CFC containing MDIs gain momentum, the FDA will play an extremely critical role in shaping the pulmonary drug delivery market. FDA's agenda will have a significant bearing on the success of a particular technology.

Phasing out of the Ozone Depleting Substance (ODS) Containing Products Presents Tremendous Growth Opportunity for Emerging Technologies

Growing environmental concern regarding the use of CFC containing products following the Montreal Protocol has limited the prospects of MDIs that are being fast replaced by non-CFC based MDIs and dry powder inhalers (DPIs). A majority of non-CFC based MDIs use hydrofluoroalkane (HFA) as a propellant. However, it is not easy to formulate drugs using HFAs, and therefore, the transition from the CFC-based MDIs is benefiting the DPIs more than the non-CFC MDIs.

Extensive research to develop non-invasive technologies as an alternative to injectable drugs in chronic diseases has resulted in the development of pulmonary drug delivery devices for diabetes, cancer, and migraine. The applications of pulmonary drug delivery are expected to further expand to many more therapeutic areas in the next few years.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.